pre-update Archives

Publication

A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk

The article, authored by Caroline Sychterz, Hong Shen, Yueping Zhang, Michael Sinz, Amin Rostami-Hodjegan, Brian…

CertaraSeptember 18, 2024

Press Release

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…

CertaraSeptember 18, 2024

Publication

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Abstract Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually…

CertaraSeptember 18, 2024

Publication

Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)

Abstract A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs)…

CertaraSeptember 18, 2024

Publication

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor…

CertaraSeptember 18, 2024

Publication

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

Abstract Incorporating an early evaluation of dosing requirements is crucial for assessing the viability of…

CertaraSeptember 18, 2024

On-Demand Webinar

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

Model Informed Drug Development (MIDD) is a critical component in the drug development process and…

CertaraSeptember 16, 2024

Guide

A Best Practice Guide to Managing Non-CRF Data

CertaraSeptember 16, 2024

Poster

Dynamic Target-Mediated Drug Disposition (TMDD)

Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the…

CertaraSeptember 16, 2024

Poster

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…

CertaraSeptember 16, 2024

pre-update

A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

A Best Practice Guide to Managing Non-CRF Data

Dynamic Target-Mediated Drug Disposition (TMDD)

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Newsletter sign up

Quick links

Solutions

Contact